Navigation Links
Herpes Drug Might Also Slow HIV Progression
Date:2/15/2010

But acyclovir is not a replacement for HIV-specific drugs, researchers say

MONDAY, Feb. 15 (HealthDay News) -- New research suggests that people who are infected with both HIV-1, a strain of the AIDS virus, and herpes simplex virus type 2 could benefit in more than one way by taking a herpes drug called acyclovir. In addition to treating herpes, the medication appears to also slow the progression of HIV.

"While the HIV-disease ameliorating effect we have observed is modest, it could add one more tool to help people with HIV infection stay healthy for longer," study co-author Dr. Jairam Lingappa, of the University of Washington, said in a news release from The Lancet.

The study, published online in the journal, analyzed what happened to almost 3,400 people in Africa who were infected with both diseases.

Half were assigned to take 400 milligrams of acyclovir twice a day, and the others took a placebo. Researchers tracked their progress for up to 24 months.

The risk of HIV progression was reduced by 16 percent in those who took acyclovir, the study found.

However, other research has suggested that acyclovir does not prevent transmission of HIV to heterosexual partners by people who take the drug, the scientists said.

The researchers said that other AIDS drugs would have a greater impact on the progression of HIV in those who were infected. But , acyclovir could be an option for people who had not progressed far enough to need antiretroviral therapy, they said.

More information

The U.S. Centers for Disease Control and Prevention has more on herpes.



-- Randy Dotinga



SOURCE: The Lancet, news release, Feb. 14, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Genital Herpes Reactivation Better Understood
2. Control of herpes symptoms does not reduce HIV transmission, international study found
3. Study shows genital herpes virus reactivates widely throughout genital tract
4. Herpes medication does not reduce risk of HIV transmission, UW-led international study finds
5. Genital Herpes May Never Go Dormant
6. VivaGel(R) Demonstrates Anti-HIV and Herpes Activity Following Human Administration
7. Scientists learn why even treated genital herpes sores boost the risk of HIV infection
8. Condoms May Reduce Herpes Risk
9. Herpes medication does not reduce risk of HIV transmission
10. Treatment Target for Herpes Pinpointed
11. Herpes: Scientists find cellular process that fights virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... NC (PRWEB) , ... January 18, 2017 , ... The ... remain on Team V, its official endurance training and fundraising team, to compete in ... V Foundation welcomes those inspired to finish the world’s oldest annual marathon to join ...
(Date:1/18/2017)... ... January 18, 2017 , ... Park Agencies ... planning services to families and business owners in the greater Kansas City area, ... with developmental disabilities. , The Lakemary Center is a comprehensive educational resource center ...
(Date:1/18/2017)... ... 2017 , ... Michael J. Hennessy Associates, Inc., (MJH), a ... Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, Jr. The ... thought leader interaction in, live video and interactive digital platforms. , In making ...
(Date:1/18/2017)... ... , ... Floundering on New Year’s resolutions? Need an excuse to get back ... The U.S. Apple Association agrees and recommends starting each day with apples, a ... heart disease. , The U.S. Apple Association – which represents apple growers and producers ...
(Date:1/17/2017)... California (PRWEB) , ... January 17, 2017 , ... ... have a point of difference. Eden Activewear is a stand-out company for several ... are exclusively online and only manufacture on demand, this is called 'Agile' manufacturing ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017 Research and Markets has ... 2017 - 2024" report to their offering. ... This new report revisits the ... that was issued in May of 2015. Self-healing is an area ... previous analysis we projected a market potential of $2.7 billion ($US) ...
(Date:1/17/2017)... -- Paragon Bioservices received a multiple-award, indefinite-delivery, indefinite-quantity ... a variety of National Institute of Allergy ... activities. The IDIQ mechanism will allow Paragon to ... awards up to $159 million. Paragon ... development of biopharmaceuticals, is one of four awardees ...
(Date:1/17/2017)... Management to Discuss Acquisition of ... KIT-302 Development On Track For An NDA ... Q1 2017   ... Holdings Ltd. (NASDAQ: KTOV ; TASE: KTOV), an innovative biopharmaceutical company, ... rd at 8:30am Eastern Time to discuss the recent acquisition of a ...
Breaking Medicine Technology: